Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MethylGene, Pharmion expand cancer deal

MethylGene (TSX:MYG) and PHRM will collaborate to develop small molecule inhibitors targeting sirtuins, a class of

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE